HC Wainwright Predicts Gossamer Bio FY2030 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – HC Wainwright issued their FY2030 earnings per share estimates for Gossamer Bio in a research report issued to clients and investors on Tuesday, February 10th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of $0.78 per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Several other equities research analysts have also issued reports on GOSS. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Barclays initiated coverage on Gossamer Bio in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $9.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

Gossamer Bio Stock Performance

Shares of NASDAQ:GOSS opened at $2.32 on Thursday. The company has a market capitalization of $536.99 million, a P/E ratio of -3.36 and a beta of 1.93. The company’s 50-day moving average is $2.88 and its 200 day moving average is $2.67. Gossamer Bio has a fifty-two week low of $0.76 and a fifty-two week high of $3.87.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Gossamer Bio by 5.2% during the third quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after buying an additional 598,981 shares during the period. Acadian Asset Management LLC increased its holdings in Gossamer Bio by 12.4% during the 2nd quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock worth $8,786,000 after acquiring an additional 787,909 shares during the period. Geode Capital Management LLC lifted its stake in Gossamer Bio by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after purchasing an additional 183,183 shares in the last quarter. Corient Private Wealth LLC lifted its stake in Gossamer Bio by 8.9% in the 2nd quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after purchasing an additional 302,200 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Gossamer Bio by 629.3% in the 3rd quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock valued at $9,519,000 after purchasing an additional 3,123,081 shares during the period. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.